Kantonsspital St.Gallen
login

Oral valganciclovir in children: single dose pharmacokinetics in a six-year-old girl

Marcus Burri, Hugh Wiltshire, Christian R. Kahlert, George Wouters & Christoph Rudin

abstract We report a pharmacokinetic study in a 6-year-old girl with congenital human immunodeficiency virus type 1 and cytomegalovirus coinfection maintained on iv ganciclovir for 6 years. Increasing infection and thrombosis caused by her iv device necessitated alternative therapy. Single dose pharmacokinetics of ganciclovir 4.4 mg/kg iv and valganciclovir 13.2 and 26.3 mg/kg po were studied with high performance liquid chromatography/tandem mass spectrometry. The two oral dosages yielded areas under the concentration curve of 14.3 and 28.7 microg x h/ml, equivalent to 43% bioavailability of ganciclovir from valganciclovir, which exceeded the area under the concentration curve of 11.1 microg x h/ml yielded by ganciclovir 4.4 mg/kg iv. Oral valganciclovir achieved therapeutic and dosage-proportional plasma concentrations in the child we studied.
   
citation Burri M, Wiltshire H, Kahlert C R, Wouters G, Rudin C. Oral valganciclovir in children: single dose pharmacokinetics in a six-year-old girl. The Pediatric infectious disease journal 2004; 23:263-6.
   
type journal paper/review (English)
date of publishing 3-2004
journal title The Pediatric infectious disease journal (23/3)
ISSN print 0891-3668
pages 263-6
PubMed 15014306